Cargando…
Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center
BACKGROUND: Guidelines for optimal sequencing of radium-223 and chemotherapy for metastatic castration resistant prostate cancer (mCRPC) do not exist. This study evaluated treatment patterns and overall survival (OS) among patients with mCRPC treated with radium-223 in an academic clinical setting....
Autores principales: | McKay, Rana R., Silver, Rebecca, Bhak, Rachel H., Korves, Caroline, Cheng, Mu, Appukkuttan, Sreevalsa, Simmons, Stacey J., Duh, Mei Sheng, Taplin, Mary-Ellen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012208/ https://www.ncbi.nlm.nih.gov/pubmed/32814846 http://dx.doi.org/10.1038/s41391-020-00271-7 |
Ejemplares similares
-
Clinical outcomes, management, and treatment patterns in patients with metastatic castration‐resistant prostate cancer treated with radium‐223 in community compared to academic settings
por: Sartor, Oliver, et al.
Publicado: (2021) -
Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014) -
Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015) -
Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
por: Cox, Heather, et al.
Publicado: (2015) -
Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)